The stock failed to hold its 50-day in February but it didn't break down; instead it went on to make new recovery highs.
It has been my longstanding belief that the stock wouldn't do much until after the June options expiration but would then start moving nicely higher as the FDA decision date of June 28 approached for key partnership drug Eliquis. Two months later, there is another key FDA decision date with Tofacitinib. Pfizer stock should do very well if both drugs are approved timely as I fully expect.
With market holding and coming back a little, with GDX showing excellent RS, with personal view that "THEY" will hold it together and kick the can and because PFE tested 21.95 successfully...I went ahead and bought some PFE.